Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kym Hoger"'
Autor:
Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, Francesca L Mordant, Zheyi Li, Michael S Avumegah, Christopher LD McMillan, Julia Lackenby, Kate Guilfoyle, Geert vanAmerongen, Koert Stittelaar, Stacey TM Cheung, Summa Bibby, Mallory Daleris, Kym Hoger, Marianne Gillard, Eve Radunz, Martina L Jones, Karen Hughes, Ben Hughes, Justin Goh, David Edwards, Judith Scoble, Lesley Pearce, Lukasz Kowalczyk, Tram Phan, Mylinh La, Louis Lu, Tam Pham, Qi Zhou, David A Brockman, Sherry J Morgan, Cora Lau, Mai H Tran, Peter Tapley, Fernando Villalón‐Letelier, James Barnes, Andrew Young, Noushin Jaberolansar, Connor AP Scott, Ariel Isaacs, Alberto A Amarilla, Alexander A Khromykh, Judith MA van denBrand, Patrick C Reading, Charani Ranasinghe, Kanta Subbarao, Trent P Munro, Paul R Young, Keith J Chappell
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 4, Pp n/a-n/a (2021)
Abstract Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational antigen design through to manufacturability and vaccine efficac
Externí odkaz:
https://doaj.org/article/75b08e009f4c4222be30bd2650f67488
Autor:
Suzanne L. Elliott, Lin-Fa Wang, Mark G. Scher, Ina Smith, Christopher J. de Bakker, Heidi J Carroll, Stephen M. Mahler, Paul M. Griffin, Martina L. Jones, Michael Gerometta, E.G. Playford, Benjamin S. Hughes, Christopher C. Broder, Kathleen D. Lynch, Reuben Klein, Kym Hoger, Edwin P. Huang, Dimiter S. Dimitrov, Stephen B. Lambert, Trent P. Munro, Karen Hughes, Margaret E. Gilmour, Debra El Saadi, Peter P. Gray
Publikováno v:
The Lancet Infectious Diseases. 20:445-454
Summary Background The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in he
Autor:
P. Mark Hogarth, Suellen Nicholson, Charani Ranasinghe, Daniel Watterson, Stavroula Corby, Bruce D. Wines, Zheyi Li, Francesca L Mordant, Damian F. J. Purcell, Christina L Henderson, Thi H. O. Nguyen, Peter Tapley, Michael S. Avumegah, Thomas Holgate, Paula Clarisa Ellenberg, Kevin J. Selva, Stacey T. M. Cheung, Luca Hensen, James G. Barnes, Naphak Modhiran, Paul M. Griffin, Katherine Kedzierska, Wuji Zhang, Kanta Subbarao, Danushka K. Wijesundara, Mai H. Tran, Patrick C. Reading, Trent P. Munro, Paul R. Young, Julia Lackenby, Amy W. Chung, Keith J. Chappell, Sara Marrero-Hernández, Kym Hoger, Jillian Bennet
Publikováno v:
The Lancet. Infectious Diseases
Background: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, an
Autor:
Naphak Modhiran, Bruce D. Wines, Paul R. Young, Katherine Kedzierska, Zhuofeng Li, Francesca L Mordant, Mai H. Tran, Paula Clarisa Ellenberg, Kevin J. Selva, Henderson Cl, Kym Hoger, Daniel Watterson, Suellen Nicholson, Keith J. Chappell, Thomas Holgate, Julia Lackenby, Patrick C. Reading, Bennet J, Luca Hensen, Danushka K. Wijesundara, Nguyen Tho, Amy W. Chung, Peter Tapley, Hogarth Pm, Stacey T. M. Cheung, Trent P. Munro, Damian F. J. Purcell, Charani Ranasinghe, Kanta Subbarao, Corby S, Sara Marrero-Hernández, Michael S. Avumegah
Publikováno v:
SSRN Electronic Journal.
Background: We assessed the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a prefusion conformation by a novel molecular clamp (Sclamp). Methods: Phase 1,
Autor:
Ariel Isaacs, Naphak Modhiran, James G. Barnes, Christopher L. D. McMillan, Koert J. Stittelaar, Tram Phan, Patrick C. Reading, Geert van Amerongen, Francesca L Mordant, Stacey T. M. Cheung, Connor Scott, Eve Radunz, Daniel Watterson, Louis Lu, Alberto A. Amarilla, Lukasz Kowalczyk, Mai Tran, Mallory Daleris, David A. Brockman, Marianne Gillard, Sherry J. Morgan, Zheyi Li, Noushin Jaberolansar, Julia Lackenby, Michael S. Avumegah, David Edwards, Kym Hoger, Karen Hughes, Judith A. Scoble, Charani Ranasinghe, Qi Zhou, Danushka K. Wijesundara, Fernando Villalon Letelier, Martina L. Jones, Ben Hughes, Kanta Subbarao, Mylinh La, Keith J. Chappell, Summa Bibby, Peter Tapley, Andrew Young, Cora Lau, Lesley A. Pearce, Tam Pham, Trent P. Munro, Paul R. Young, Alexander A. Khromykh, Justin B. Goh, Kate Guilfoyle
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate vaccines now in clinical evaluation. Here we describe the preclinical development of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1f9211287e21428829cd16fc490c77f
https://doi.org/10.21203/rs.3.rs-68892/v1
https://doi.org/10.21203/rs.3.rs-68892/v1
Autor:
Francesca L Mordant, Danushka K. Wijesundara, Keith J. Chappell, Cora Lau, Naphak Modhiran, Kanta Subbarao, Stacey T. M. Cheung, Ariel Isaacs, Charani Ranasinghe, Julia Lackenby, Martina L. Jones, Qi Zhou, Eve Radunz, James G. Barnes, Kate Guilfoyle, Koert J. Stittelaar, Zheyi Li, Peter Tapley, Justin B. Goh, Tram Phan, Karen Hughes, Judith M. A. van den Brand, Noushin Jaberolansar, Benjamin S. Hughes, Sherry J. Morgan, Connor A. P. Scott, Judith A. Scoble, Trent P. Munro, Tam Pham, Patrick C. Reading, Mai H. Tran, Andrew Young, Fernando Villalón-Letelier, Marianne Gillard, Lesley A. Pearce, Michael S. Avumegah, Mylinh La, Summa Bibby, Christopher L. D. McMillan, Daniel Watterson, Lukasz Kowalczyk, Mallory Daleris, Paul R. Young, Louis Lu, Alberto A. Amarilla, Alexander A. Khromykh, David Edwards, Kym Hoger, Geert van Amerongen, David A. Brockman
Publikováno v:
SSRN Electronic Journal.
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace. Here we describe rational antigen design through to manufacturability and vaccine efficacy, of a prefusion-stabili
Autor:
Peter P. Gray, Karen Hughes, Martina L. Jones, Michael Gerometta, Stephen B. Lambert, Christopher C. Broder, Edwin P. Huang, Suzanne L. Elliott, Lin-Fa Wang, Benjamin S. Hughes, Dimiter S. Dimitrov, Stephen M. Mahler, Heidi J Carroll, Kathleen D. Lynch, Trent P. Munro, Mark G. Scher, Ina Smith, Paul M. Griffin, Reuben Klein, Margaret E. Gilmour, Christopher J. de Bakker, Debra El Saadi, E.G. Playford, Kym Hoger
Publikováno v:
SSRN Electronic Journal.
Background: The henipaviruses, Hendra virus and Nipah virus, are emerging zoonotic pathogens of bat origins that have been associated with poor clinical outcomes in humans. The monoclonal antibody (mAb) m102∙4 is a potent fully human antibody that